Skin and Oral Cavity Cancer (CMN)
Following the approval from the Institutional Review Board (IRB), IFO is initiating their first study of Alpha DaRT for the treatment of Skin Cancer of all types including Squamous Cell Carcinoma (SCC), Basal Cell Carcinoma (BCC), Merkel Cell Carcinoma (MCC) and Melanoma. Those types of skin cancer are called Cutaneous and Mucosal malignant Neoplasia (CMN).
The trials in Rome will be led by principal investigator Laura Eibenschutz, MD, Medical Director at the Department of Oncological Dermatology from IFO, ISG. “With strong, well-published findings from preclinical trials in over 6000 animals in different types of tumors, we are proud to start Alpha TAU’s first trial investigating the Alpha DaRT as a treatment for Cutaneous and Mucosal malignant Neoplasia (CMN),” said Dr. Laura Eibenschutz, IFO.
The treatment for CMN, similar to SCC, is conducted under local anesthesia in a regular procedure room. No special shielding or equipment is required.
Each patient is treated under local anesthesia in a single short session. The treatment is delivered by inserting Alpha DaRT seeds into to the tumor. Using ultra-minimally invasive applicators minimizes patient discomfort and improves the aesthetic outcome of the procedure. The Alpha DaRT seeds are stringed on a suture which enables the seeds’ removal according to the doctor's decision and evaluation of necessity.
In most cases, the patient is released from the clinic immediately after the procedure. Follow-up examinations are conducted throughout the trial to ensure the patient’s safety and to record necessary data.
Ongoing Clinical Trials
Treatment of Cutaneous and Mucosal malignant Neoplasia (CMN) is currently running at: